로딩 중...
52주 최고가 대비 98.7% 위치
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $203.6M | $245.1M | $313.0M | $376.6M |
| 영업이익 | - | $-249.0M | $-206.9M | $-175.9M | $-136.3M |
| 당기순이익 | - | $-217.9M | $-204.6M | $-208.7M | $-77.7M |
| 잉여현금흐름 (FCF) | - | $-226.2M | $-170.3M | $-69.2M | $-75.6M |
| 수익성 비율 | |||||
| 영업이익률 | - | -122.3% | -84.4% | -56.2% | -36.2% |
| 순이익률 | - | -107.0% | -83.5% | -66.7% | -20.6% |
| ROE (자기자본이익률) | - | -27.6% | -32.8% | -44.2% | -16.4% |
| ROA (자산이익률) | - | -22.7% | -26.4% | -34.0% | -12.1% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 20.4% | 27.7% | 20.3% |
| EPS 성장률 (YoY) | - | - | 10.9% | 0.0% | 63.9% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | - |
| PBR (주가순자산배수) | - | 2.6x | 1.6x | 5.3x | 4.3x |
| PSR (주가매출배수) | - | 10.0x | 4.0x | 8.0x | 5.4x |
| FCF Yield | - | -11.1% | -17.3% | -2.8% | -3.7% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.12 | 0.15 | 0.18 | 0.16 |
| 유동비율 | - | 6.58 | 5.79 | 4.88 | 3.64 |
MOLINA HEALTHCARE INC
$179.86
$9.4B